Drug Profile
BIBB 575
Latest Information Update: 18 Jun 2001
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 18 Jun 2001 No-Development-Reported for Hyperlipidaemia in Germany (Unknown route)
- 08 May 1998 New profile
- 08 May 1998 Preclinical development for Hyperlipidaemia in Germany (Unknown route)